Isosceles Pharmaceuticals

Isosceles Pharmaceuticals is developing IPI201, a proprietary, IV-formulated synthetic small-molecule immunotherapy adjuvant built around the hypothesis that converting immunologically cold tumors into hot ones would let existing checkpoint inhibitors work for many more cancer patients. Rather than targeting a single receptor, IPI201 uses a multi-pathway mechanism designed to act on innate immunity, anti-inflammatory signaling, and tissue perfusion simultaneously to convert a tumor's immunological state. The company describes itself as building a platform mechanism rather than a single drug, positioning IPI201 as the realization of its core hypothesis about converting cold tumors to hot.